In his recent speech on the need for NHS reform, the prime minister announced that support for preventative care in communities would be at the heart of the Government’s approach.
Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.